MULTIPLONAL HUMAN ANTIBODIES TO PROGRAMMABLE DEATH 1 (PD) PROTEIN AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNE-MEDICINES

摘要

1. A method of inhibiting the growth of tumor cells in an individual, comprising:! (a) administering a monoclonal anti-PD-1 antibody to an individual, and! (b) administering a monoclonal anti-CTLA-4 antibody to an individual. ! 2. The method according to claim 1, where the tumor cells are cancer cells selected from the group consisting of melanoma, kidney cancer, prostate cancer, breast cancer, colon cancer and lung cancer. ! 3. The method according to claim 1, where the tumor cells are cancer cells selected from the group consisting of bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular malignant melanoma, uterine cancer, ovarian cancer, cancer rectal cancer, anal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin’s disease, non-Hodgkin’s lymphoma, esophageal cancer, small intestine cancer, endocrine cancer thyroid cancer systems s, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethra cancer, penis cancer, chronic or acute leukemia, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of children, lymphocytic cancer bladder, cancer of the kidneys or ureter, cancer of the renal pelvis, neoplasm of the central nervous system (CNS), primary lymphoma of the central nervous system, tumor angiogenesis, spinal cord tumor, glioma of the brain stem, and ene pituitary, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, malignant zabole